Market Overview

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

Share:
Related ENDP
Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
5 Stocks Cut In Half In 2016

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.

In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”

Endo Health Solutions closed on Thursday at $35.96.

Latest Ratings for ENDP

DateFirmActionFromTo
Jun 2016BMO CapitalInitiates Coverage onMarket Perform
Jun 2016Mizuho SecuritiesUpgradesUnderperformNeutral
Jun 2016Goldman SachsInitiates Coverage onNeutral

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Corey Davis JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ENDP)

View Comments and Join the Discussion!